CAS 1262414-04-9

Cenerimod

Description:

Cenerimod is a synthetic chemical compound primarily investigated for its potential therapeutic applications, particularly in the treatment of autoimmune diseases such as systemic lupus erythematosus (SLE). It functions as a selective modulator of the sphingosine-1-phosphate (S1P) receptor, which plays a crucial role in lymphocyte trafficking and immune response regulation. By modulating this receptor, Cenerimod aims to reduce the migration of immune cells to inflamed tissues, thereby potentially alleviating symptoms associated with autoimmune conditions. The compound is characterized by its specific binding affinity to the S1P receptor, which distinguishes it from other immunomodulatory agents. Additionally, Cenerimod's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion, is designed to optimize its therapeutic efficacy while minimizing side effects. Ongoing clinical trials are assessing its safety and effectiveness, contributing to the understanding of its role in managing autoimmune disorders. As research progresses, Cenerimod may offer a novel approach to treatment in this therapeutic area.

Synonyms:

• T14924
• 1,2-Propanediol, 3-[4-[5-(2-cyclopentyl-6-methoxy-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-, (2S)-
• (S)-3-(4-(5-(2-CYCLOPENTYL-6-METHOXYPYRIDIN-4-YL)-1,2,4-OXADIAZOL-3-YL)-2-ETHYL-6-METHYLPHENOXY)PROPANE-1,2-DIOL
• ACT-334441

1,2-Propanediol, 3-[4-[5-(2-cyclopentyl-6-methoxy-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-, (2S)-

CAS: 1262414-04-9

Formula: C₂₅H₃₁N₃O₅

Purity: 95%

Molecular weight: 453.5307

Ref: IN-DA000SEW

Cenerimod

CAS: 1262414-04-9

Cenerimod

Purity: ≥95%

Molecular weight: 453.53g/mol

Ref: 54-BUP17566

Cenerimod

CAS: 1262414-04-9

Cenerimod is a small molecule that inhibits the activity of TNF-α and IL-1β, which are pro-inflammatory cytokines. It has been shown to reduce clinical response and disease activity in patients with inflammatory bowel disease (IBD) and Crohn’s disease. Cenerimod is administered orally, and the pharmacokinetic properties have been characterized in healthy volunteers and patients with hepatic impairment or autoimmune diseases. The terminal half-life of cenerimod ranges from 3 to 5 hours, depending on the condition of the patient. The drug undergoes extensive first-pass metabolism, primarily by CYP3A4, CYP2C8, CYP2C9, CYP2C19, and UGT1A6 enzymes. Cenerimod is eliminated primarily through biliary excretion as metabolites; it does not bind to plasma proteins.

Formula: C₂₅H₃₁N₃O₅

Purity: Min. 95%

Molecular weight: 453.53 g/mol

Ref: 3D-MAC41404

Cenerimod

CAS: 1262414-04-9

Cenerimod (ACT-334441) is an S1P1 agonist used in the study of murine experimental autoimmune encephalomyelitis (EAE) and murine scleroderma.

Formula: C₂₅H₃₁N₃O₅

Purity: 97.43% - 99.97%

Color and Shape: Solid

Molecular weight: 453.53

Ref: TM-T14924